Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1440329 | 1.00 | CYP3A4 (0.50) | CYP3A4KDM4EALDH1A1KMT2AMAPT | |
| SCHEMBL5368566 | 1.00 | CYP3A4 (0.50) | CYP3A4KDM4EALDH1A1KMT2AMAPT | |
| SCHEMBL4249938 | 1.00 | CYP3A4 (0.50) | CYP3A4KDM4EALDH1A1KMT2AMAPT | |
| SCHEMBL15325590 | 1.00 | CYP3A4 (0.50) | CYP3A4KDM4EALDH1A1KMT2AMAPT | |
| SCHEMBL19408855 | 1.00 | CYP3A4 (0.50) | CYP3A4KDM4EALDH1A1KMT2AMAPT | |
| SCHEMBL24938939 | 1.00 | CYP3A4 (0.50) | CYP3A4KDM4EALDH1A1KMT2AMAPT | |
| Hydrochloric Acid SCHEMBL6951431 | 0.99 | CYP3A4 (0.49) | CYP3A4KDM4EALDH1A1KMT2AMAPT | |
| SCHEMBL9962426 | 0.89 | MAPT (0.51) | CYP3A4KDM4EALDH1A1KMT2AMAPT | |
| SCHEMBL2919878 | 0.88 | CYP3A4 (0.53) | CYP3A4KDM4EALDH1A1KMT2AMAPT | |
| SCHEMBL2919874 | 0.88 | CYP3A4 (0.53) | CYP3A4KDM4EALDH1A1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250134869-A1 | Pyrrolo[2,3-d]pyrimidinyl, Pyrrolo[2,3-b]pyrazinyl and Pyrrolo[2,3-d]pyridinyl Acryla-mides | PFIZER INC (US) | 2025-05-01 | — | — | US | disclosed |
| US-12077533-B2 | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides | PFIZER INC. (US) | 2024-09-03 | — | — | US | disclosed |
| US-20240246988-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2024-07-25 | — | — | US | disclosed |
| US-11938114-B2 | Bacterial efflux pump inhibitors | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2024-03-26 | — | — | US | disclosed |
| US-20230046457-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BIOGEN MA INC. | 2023-02-16 | — | — | US | disclosed |
| US-20230009153-A1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES | PFIZER INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-11111242-B2 | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides | PFIZER INC. (US) | 2021-09-07 | — | — | US | disclosed |
| US-20210137881-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | RUTGERS, THE STATE UNIVERISTY OF NEW JERSEY (US) | 2021-05-13 | — | — | US | disclosed |
| EP-3318565-B1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES | PFIZER (US) | 2021-04-14 | — | — | EP | disclosed |
| US-20200399283-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | VIRACTA THERAPEUTICS, INC. | 2020-12-24 | — | — | US | disclosed |
| EP-2155672-A1 | PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2010-02-24 | — | — | EP | disclosed |
| US-7615669-B2 | Process for producing fluoro-compounds | TOSOH F-TECH, INC. (JP) | 2009-11-10 | — | — | US | disclosed |
| US-7528136-B2 | for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD); 2-{4-[(2S,4S)-1-benzyl-4-(2,4-difluoro-benzylamino)-pyrrolidine-2-carbonyl]-piperazin-1-yl}-benzonitrile | HOFFMANN-LA ROCHE INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20090030228-A1 | Process for producing fluoro-compounds | TOSOH F-TECH, INC. (JP) | 2009-01-29 | — | — | US | disclosed |
| WO-2008148689-A1 | PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-12-11 | — | — | WO | disclosed |
| US-20080306086-A1 | PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2008-12-11 | — | — | US | disclosed |
| EP-1903021-A1 | PROCESS FOR PRODUCTION OF FLUOROCOMPOUNDS | Tosoh F-Tech, Inc. (JP) | 2008-03-26 | — | — | EP | disclosed |
| WO-2003104249-A1 | NOVEL LINKER FOR NUCLEOTIDES | NEXGEN BIOTECHNOLOGIES, INC. (KR) | 2003-12-18 | — | — | WO | disclosed |
| EP-0636133-A1 | SUBSTITUTED 3-PYRROLIDINYLTHIO-CARBAPENEMS AS ANTIMICROBIAL AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-02-01 | — | — | EP | disclosed |
| CN-1082547-A | Azabicyclic compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-02-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246988-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | CYP3A4 4327/4885KDM4E 1208/4885ALDH1A1 4783/4885 |
| US-20230046457-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | CYP3A4 4327/4885KDM4E 1208/4885ALDH1A1 4783/4885 |
| US-11938114-B2 | Bacterial efflux pump inhibitors | ABCB11, ABCB1, SLC47A1 | CYP3A4 621/4885KDM4E 4380/4885ALDH1A1 1075/4885 |
| US-12077533-B2 | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides | ACR, PKD2, PGA5 | CYP3A4 1574/4885KDM4E 2589/4885ALDH1A1 637/4885 |
| US-11111242-B2 | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides | JAK2, JAK3, JAK1 | CYP3A4 2269/4885KDM4E 1306/4885ALDH1A1 1079/4885 |
| US-20210137881-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | ABCB11, ABCB1, SLC47A1 | CYP3A4 621/4885KDM4E 4380/4885ALDH1A1 1075/4885 |
| US-20250134869-A1 | Pyrrolo[2,3-d]pyrimidinyl, Pyrrolo[2,3-b]pyrazinyl and Pyrrolo[2,3-d]pyridinyl Acryla-mides | JAK2, JAK3, JAK1 | CYP3A4 2441/4885KDM4E 1075/4885ALDH1A1 1113/4885 |
| US-20200399283-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | CYP3A4 4327/4885KDM4E 1208/4885ALDH1A1 4783/4885 |
| US-20080306086-A1 | PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS | SLC6A3, OPRL1, OPRK1 | CYP3A4 2026/4885KDM4E 1663/4885ALDH1A1 868/4885 |
| US-20230009153-A1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES | JAK2, JAK3, JAK1 | CYP3A4 2469/4885KDM4E 2089/4885ALDH1A1 1206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.